




EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Regulation of veterinary medicinal products in the 21st century – Addressing challenges and opportunities across the European Regulatory Framework

EMA's Regulatory Science Response

Veterinary Stakeholders Workshop

Presented by Ivo Claassen on 6 December 2018
Head of Veterinary Medicines Division, EMA




An agency of the European Union





Why now?



To monitor and sign-post emerging and future trends in science and technology



To identify key priorities where new or enhanced engagement is essential to the continued success of the Agency's mission



To prioritise use of resources and external collaborations to strategically advance regulatory science



To shape and influence the vision for the EU Medicines Agencies Network (EMRN) Strategy 2020–25



How does EMA define Regulatory Science?


- Regulatory science is defined as a range of scientific disciplines that are applied to the quality, safety and efficacy assessment of (**veterinary**) medicinal products and that inform regulatory decision-making throughout the lifecycle of a medicine.
- It encompasses basic and applied (**veterinary**) medicinal science and social sciences, and contributes to the development of regulatory standards and tools.






The role of regulatory science at EMA?

View 1



View 2






Vision—EMA Regulatory Science to 2025

“

To foster scientific
excellence in the regulation of veterinary
medicines for the benefit of animal and public
health while facilitating and promoting innovation
and access to novel medicinal products.

”







Strategic goal 1

To catalyse the integration of science and technology in drug development.



Strategic goal 2

To drive collaborative evidence generation to improve the scientific quality of evaluations.



Strategic goal 3

To address emerging health threats and availability/therapeutic challenges.



Strategic goal 4

To enable and leverage research and innovation in regulatory science.



EMA Regulatory Science to 2025 - Timeline



Legislation follows science, not the other way round:
embracing innovation ambition beyond implementation of NVR?



CVMP

David Murphy,
Chair of CVMP



Nancy de Briyne,
FVE



European
Commission

Christian Siebert,
DG Santé



Jean-Pierre Orand,
HMA Management
Group



Alexander Böttner,
AnimalhealthEurope